With key results expected from its lead cancer program this year, the cancer drug specialist Tesaro has stocked its coffers with $91.2 million from a public stock offering.
Singapore-based TauRx has reeled in $10.5 million from one of its unconventional investors, adding to the $300 million the company says it has already raised to back a slate of Phase III studies for an experimental Alzheimer's therapy.
Tetraphase Pharmaceuticals hopes that the next phase for the biotech is as a public company.
With Big Pharma outfits pursuing the same big target, biotech startup Dezima Pharma has landed first-round venture and loan financing totaling $18.6 million to advance a compound in the controversial class of cholesterol drugs known as CETP inhibitors.
The new CEO at Kala Pharmaceuticals has landed an $11.5 million A round and mapped out plans to devote much of the cash to lead programs on wet, age-related macular degeneration and ocular inflammation.
Third Rock Ventures has made quite a few big biotech gambles in recent years. And now we know just how well one of them paid off. In a 10-K filed with the SEC, Shire detailed--for the first time-- its $49.3 million upfront payment to acquire Lotus Tissue Repair, which the venture group had a controlling interest in. And Shire added $275 million in milestones, to further sweeten the package. Read more >>
Miami-based Brickell Biotech grabbed $7 million in a new venture round led by a South Korean cosmetics company to back its work on new chemical entities for dermatology.
Intersect ENT nailed down $30 million in new Series D funding that attracted major investor interest from Medtronic and a number of other high-profile players.
Seattle-based startup Blaze Bioscience has nailed an $8.5 million A round, giving it the money it needs to hire on a pair of key players, lease a new lab and headquarters space and prep its lead imaging product for the clinic.
Living Proof has another $30 million in venture cash to get commercialization work in gear, while bankrolling some fresh efforts on the scientific side of the hair care venture.